Patent Application for HCMV Gp34- and Gp68-Specific Antibodies Reveals Novel Therapeutic and Diagnostic Approaches

Strategic Insights -

A patent application filed by a team of researchers from the Albert-Ludwigs-Universitaet Freiburg in Germany, led by Harmut Hengel, has disclosed novel antibodies and antigen binding fragments targeting the extracellular domains of human cytomegalovirus (HCMV) glycoproteins gp34 and gp68. The application, filed on June 10, 2022, and made available online on August 28, 2025, provides a comprehensive overview of the development of these antibodies and their potential therapeutic and diagnostic applications.

The researchers' background information highlights the pressing need for an effective vaccine against congenital CMV infection, which is one of the most significant challenges in cytomegalovirus research. The development of a vaccine to prevent congenital CMV is considered a top priority by the US Institute of Medicine of the National Academy of Science. The researchers' team sought to address this need by generating mouse monoclonal antibodies that can block the immunoevasive function of gp34 and gp68, which are thought to be responsible for limiting the efficacy of endogenous and therapeutic IgG antibodies directed against HCMV antigens.

The patent application discloses the generation of two mouse monoclonal antibodies targeting the extracellular domains of gp34 and gp68. The antibodies were designed to bind to specific regions of these glycoproteins, thereby blocking their interaction with Fc receptors and restoring FcR-mediated immune responses. The researchers demonstrate that these antibodies can effectively block the binding of gp34 and gp68 to Fc receptors, including the neonatal Fc receptor, and restore the natural function of the neonatal Fc receptor.

Key Takeaways:

  • The patent application discloses novel antibodies and antigen binding fragments targeting the extracellular domains of gp34 and gp68.
  • The researchers generated mouse monoclonal antibodies that can block the immunoevasive function of gp34 and gp68, restoring FcR-mediated immune responses.
  • The antibodies were designed to bind to specific regions of gp34 and gp68, preventing their interaction with Fc receptors.
  • The researchers demonstrate that these antibodies can effectively block the binding of gp34 and gp68 to Fc receptors, including the neonatal Fc receptor.
  • The antibodies show promise in preventing congenital CMV infection and treating HCMV-related diseases.
  • The patent application provides a comprehensive overview of the development of these antibodies and their potential therapeutic and diagnostic applications.
  • The researchers highlight the importance of developing effective vaccines and therapeutic approaches to prevent congenital CMV infection.

Statistics:

  • 2 mouse monoclonal antibodies targeting gp34 and gp68 were generated.
  • The antibodies were designed to bind to specific regions of gp34 and gp68, preventing their interaction with Fc receptors.
  • The researchers demonstrate that these antibodies can effectively block the binding of gp34 and gp68 to Fc receptors, including the neonatal Fc receptor.
  • The antibodies show promise in preventing congenital CMV infection and treating HCMV-related diseases.
  • The patent application was filed on June 10, 2022, and made available online on August 28, 2025.

Sources:

  • HENGEL, Harmut; HOFFMAN, Katja; JONJIC, Stipan; KOLB, Philipp Leonhard; LENAC-ROVIS, Tihana. Application Of Hcmv Gp34- And Gp68-Specific Antibodies And Fragments Thereof For Prevention, Therapy And Diagnostics Of Hcmv Disease. U.S. Patent Application Number 20250270295, filed June 10, 2022 and posted August 28, 2025. Patent URL (for desktop use only): https://ppubs.uspto.gov/pubwebapp/external.html?q=(20250270295)&db=US-PGPUB&type=ids